白三烯受体 (cys-LTs) 是一类强效生物活性脂质,通过两种结构不同的 G 蛋白偶联受体(称为 CysLT1 和 CysLT2 受体)发挥作用。半胱氨酰白三烯 LTC4、LTD4 和 LTE4 是人类支气管哮喘的重要介质。白三烯受体是 G 蛋白偶联受体超家族的成员,使用磷脂酰肌醇-钙第二信使系统。LTD4 激活 CysLT1 会导致平滑肌收缩和增殖、水肿、嗜酸性粒细胞迁移和肺粘液层损伤。白三烯受体拮抗剂(简称 LTRA)是一类非甾体类口服药物。它们也可以称为抗炎支气管收缩预防剂。LTRA 通过阻断可能导致呼吸道炎症的化学反应发挥作用。
Leukotriene Receptor (cys-LTs) are a family of potent bioactive lipids that act through two structurally divergent G protein-coupled receptors, termed the CysLT1 and CysLT2 receptors. The cysteinyl leukotrienes LTC4, LTD4, and LTE4 are important mediators of human bronchial asthma. Leukotriene Receptor is a member of the superfamily of G protein-coupled receptors and uses a phosphatidylinositol-calcium second messenger system. Activation of CysLT1 by LTD4 results in contraction and proliferation of smooth muscle, oedema, eosinophil migration and damage to the mucus layer in the lung. Leukotriene receptor antagonists, called LTRAs for short, are a class of oral medication that is non-steroidal. They may also be referred to as anti-inflammatory bronchoconstriction preventors. LTRAs work by blocking a chemical reaction that can lead to inflammation in the airways.
(5S,6R)-DiHETEs 是 (5S,6R)-DiHETE (MS-J46987) 的异构体,后者可被白三烯受体 (LTD4 受体) 识别,并能诱导豚鼠离体回肠收缩,EC50 为 1.3 μM,该作用可被 LTD4 受体拮抗剂抑制。
© 2026 MolStrong. 保留所有权利。粤ICP备2023004355号
可通过CAS号进行批量搜索,一行一个CAS号